Abstracts tagged "immunology"

Abstract Number: 0015 • ACR Convergence 2022
Differential Antigen Binding of Closely Related Monoclonal ACPA
Caroline Grönwall¹, Anatoly Dubnovitsky¹, Philip Titcombe², Daniel Mueller² and vivianne malmström¹, ¹Karolinska Institutet, Stockholm, Sweden, ²University of Minnesota, Minneapolis, MN
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are a hallmark of rheumatoid arthritis (RA) and the clonality and antigen targets of ACPA positive B cells can be…
Abstract Number: 0568 • ACR Convergence 2022
The Absence of Blk Leads to Increased Inflammation in a Murine Model of Kawasaki Disease
Melissa Kleinau¹, Mohammed Massumi², Lysa Langevin², Paul Tsoukas², Harper Cheng², Suzanne Tam², Trang Duong² and Rae Yeung³, ¹University of Toronto, Toronto, ON, Canada, ²Peter Gilgan Centre for Research and Learning, Toronto, ON, Canada, ³The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Kawasaki Disease (KD) is the leading cause of acquired heart disease in children in developed countries characterized by inflammation of the coronary arteries leading…
Abstract Number: 0755 • ACR Convergence 2022
Immune Responses and Disease Marker Changes Following SARS-CoV-2 mRNA Vaccination in a Cohort of Rheumatic Disease Patients
Zesheng An¹, Xian Zhou¹, Yanfeng Li¹, Jane Jaquith¹, Kathleen McCarthy-Fruin¹, Kenneth J. Warrington¹, Ali Duarte-Garcia¹, Uma Thanarajasingam¹, Cornelia M. Weyand² and Hu Zeng¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic School of Medicine, Rochester, MN, and Stanford University, Stanford, CA
Background/Purpose: The immunological responses following 3 doses of SARS-CoV2 mRNA vaccination in rheumatic disease patients are unclear. Furthermore, the impact of SARS-CoV2 mRNA vaccination on…
Abstract Number: 1166 • ACR Convergence 2022
Scleroderma Fibroblasts Induce Alternative Macrophage Activation via an ERK1/2-dependent Mechanism
Taha Dinc¹, Juan-Pablo Zertuche¹, Fatima El Adili², Maria Trojanowska³ and Andreea Bujor³, ¹Boston University School of Medicine, Boston, MA, ²Boston University School of Medicine, Revere, MA, ³Boston University, Boston, MA
Background/Purpose: Activation of the innate immune system in systemic sclerosis (SSc), with an increased number of profibrotic/alternatively-activated macrophages in affected tissues, is an important aspect…
Abstract Number: 1704 • ACR Convergence 2022
Interaction of Macrophages and Natural Killer Cells in Pathogenesis of HIV-1-Associated Inflammatory Arthritis
Can Sungur¹, Gao Hongbo¹, Li-ping Yang², Liang Shan¹ and Wayne Yokoyama³, ¹Washington University, St. Louis, MO, ²Washington University in St. Louis, St. Louis, MO, ³Washington University School of Medicine, St. Louis, MO
Background/Purpose: Human immunodeficiency virus (HIV) remains a significant life-threatening agent and burden on public health. Lesser studied and understood aspects of HIV infections include HIV-associated…
Abstract Number: 1851 • ACR Convergence 2022
Phenotype and Genotype of Adult-onset Adenosine Deaminase 2 Deficiency Patients
Beibei Zu¹, rongrong wang², Xiaorou Wang³, Bingqing Zhang⁴, Na Xu⁴, Chengjin Huang⁴, Min Shen⁵ and Xuejun Zeng⁴, ¹Department of Rheumatology, Xuzhou Central Hospital, XuZhou, China, ²Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China, ³Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, Beijing, China, ⁴Department of General Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, ⁵Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China
Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive autoinflammatory disease, characterized by early‑onset vasculopathy, fever, strokes, livedoid rash, hepatosplenomegaly, and hematologic dysfunction,…
Abstract Number: 0038 • ACR Convergence 2022
STING Antagonist (IFM4490) Inhibits STING Activation and STING Dependent Signal Transduction in Patients with STING-associated Vasculopathy with Onset in Infancy (SAVI)
Sachin Gaurav¹, Bin Lin², Sophia Park³, Shankar Venkatraman⁴, David Winkler⁴ and Raphaela Goldbach-Mansky⁵, ¹Translational Autoinflammatory Diseases Section, LCIM, NIAID,, Bethesda, MD, ²NIH, Bethesda, MD, ³NIAID, Bethesda, MD, ⁴IFM Therapeutics, Boston, MA, ⁵NIH/NIAID, Potomac, MD
Background/Purpose: SAVI is a rare, autoinflammatory type I interferonopathy caused by gain-of-function mutations that cause STING activation and excessive production of type I interferons and…
Abstract Number: 0583 • ACR Convergence 2022
Toll-Like Receptor Ligands Stimulated Monocyte-Derived Langerhans Cell-Like Dendritic Cells Induce Psoriasis-Related Molecules, IL-23 and Delta-Like-4
Rei Takahashi¹, Kohei Maeda¹, Toshihiro Tanioka¹ and Takeo Isozaki², ¹Division of Pathogenesis and Translational Medicine, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan, ²Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
Background/Purpose: Monocyte-derived Langerhans cell-like dendritic cells (Mo-LCs) are involved in epidermal disorders such as psoriasis in murine models. However, the roles of Mo-LCs in the…
Abstract Number: 0759 • ACR Convergence 2022
Immunogenicity of COVID-19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Diseases (AIIRD) on Immunomodulatory Therapies (IMT): An Updated Cohort Study
Gordon Lam¹, Andrew Laster¹, Heather Gladue¹, Ahmad Kashif¹, Erin Siceloff², Victoria Lackey¹, Cheryl Robertson¹, Ashley Toci¹, Maggie McCarter³ and Leonard Calabrese⁴, ¹Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ²Arthritis and Osteoporosis Consultants of the Carolinas, Stallings, NC, ³University of South Carolina, Columbia, SC, ⁴Cleveland Clinic, Cleveland, OH
Background/Purpose: AIIRD patients may have a blunted immune response to the COVID-19 vaccines, but this is uncertain as these individuals were not included in clinical…
Abstract Number: 1171 • ACR Convergence 2022
Distinct Immune Cell Subsets in Systemic Sclerosis-related Interstitial Lung Disease
Phan Saligrama¹, Erin Wilfong², Elise Rizzi³, Leslie Crofford² and Peggy Kendall¹, ¹Washington University, Saint Louis, MO, ²Vanderbilt University Medical Center, Nashville, TN, ³Pennsylvania State University, Hershey, PA
Background/Purpose: The pathogenesis of systemic sclerosis is not well understood. The key differences between immune cell compartments in scleroderma with and without interstitial lung disease…
Abstract Number: 1705 • ACR Convergence 2022
Peptidoglycan Amplifies CD4+ T Cell Activation by MHCII+ Fibroblast-like Synoviocytes in an in Vitro Model of Lyme Arthritis
Joseph Rouse¹, Amanda Wahhab¹, Rebecca Danner¹, Brandon Jutras², Adam Edelstein³, Klemen Strle⁴ and Robert Lochhead⁵, ¹Medical College of Wisconsin, Milwaukee, WI, ²Virginia Tech, Blacksburg, VA, ³Northwestern Medicine, Chicago, IL, ⁴Wadsworth Center, Albany, NY, ⁵Medical College of Wisconsin, Germantown, WI
Background/Purpose: Lyme arthritis (LA), caused by infection with Borrelia burgdorferi (Bb), is characterized by proliferative synovitis accompanied by dysregulated autoimmune Th1 responses. Fibroblast-like synoviocytes (FLS)…
Abstract Number: 1936 • ACR Convergence 2022
A De Novo Dominant-negative PSMB8 mutation is Linked to a More Severe CANDLE-like Phenotype
Sara Alehashemi¹, Adriana Almeida de Jesus², Jonas Johannes Papendorf³, Farzana Bhuyan⁴, Kat Uss⁵, Anvitha Metpally⁶, Bin Lin⁷, Sophia Park⁸, Thais C.L. Moura⁹, Renata R Dias⁹, Mayra B. Dorna⁹, Katia Kozu⁹, Adriana Sallum⁹, Lucia M. A. Campos⁹, Gijs Santen¹⁰, Jesper Kers¹⁰, Onno Teng¹¹, Karin Palmblad¹², Tom Huizinga¹⁰, Frédéric Ebstein¹³, Elke Krüger¹³ and Raphaela Goldbach-Mansky¹⁴, ¹NIH/NIAID/TADS, Clarksville, MD, ²NIAID, NIH, Silver Spring, MD, ³Institut für Medizinische Biochemie und Molekularbiologie, Universitätsmedizin Greifswald, Greifswald, Germany, ⁴National Institutes of Health, Bethesda, MD, ⁵National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ⁶NIAID, NIH, Bethesda, MD, ⁷NIH, Bethesda, MD, ⁸NIAID, Bethesda, MD, ⁹Children's Hospital of the University of São Paulo, São Paulo, Brazil, ¹⁰Leiden University Medical Center, Leiden, Netherlands, ¹¹Leiden University Medical Center, Leiderdorp, Netherlands, ¹²Karolinska University Hospital, Stockholm, Sweden, ¹³Institut für Medizinische Biochemie und Molekularbiologie (IMBM), Universitätsmedizin Greifswald, Greifswald, Germany, ¹⁴NIH/NIAID, Potomac, MD
Background/Purpose: Homozygote (HM)/compound heterozygote (CH) and digenic (DG) mutations in proteasome subunits cause the autoinflammatory syndrome CANDLE, or proteasome-associated autoinflammatory syndrome (PRAAS). Inflammation is mediated…
Abstract Number: L02 • ACR Convergence 2021
COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases
Ines Colmegna¹, Mariana Useche¹, Emmanouil Rampakakis², Nathalie Amiable³, Emmanuelle Rollet-Labelle³, Louis Bessette⁴, Jo-Anne Costa⁴, Marc Dionne⁴, Mary-Ann Fitzcharles², Elizabeth Hazel², Deirdre McCormack², Laetitia Michou⁴, Pantelis Panopalis², Marc-Andre Langlois⁵, Sasha Bernatsky⁶ and Paul R. Fortin⁷, ¹The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²McGill University Health Centre, Montreal, QC, Canada, ³Centre de Recherche du CHU de Quebec, Quebec, Canada, ⁴Universite Laval, Quebec, QC, Canada, ⁵University of Ottawa, Ottawa, ON, Canada, ⁶McGill University, Montreal, QC, Canada, ⁷CHU de Quebec - Universite Laval, Quebec, Canada
Background/Purpose: Immunocompromised conditions and/or a history of autoimmune disease were exclusion criteria of the initial SARS-CoV-2 vaccines clinical trials. We assessed the safety and immunogenicity…
Abstract Number: L20 • ACR Convergence 2021
Efficacy of Emapalumab, an Anti-IFNγ Antibody in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (sJIA) Who Had Failed High-Dose Glucocorticoids (GCs)
Fabrizio De Benedetti¹, Alexei Grom², Paul Brogan³, Claudia Bracaglia¹, Manuela Pardeo¹, Giulia Marucci¹, Despina Eleftheriou³, Charalampia Papadopoulou³, Pierre Quartier⁴, Jordi Antón⁵, Rikke Frederiksen⁶, Veronica Asnaghi⁶ and Cristina De Min⁶, ¹Bambino Gesù Children's Hospital IRCCS, Rome, Italy, ²Cincinnati Children’s Hospital, Division of Rheumatology, Cincinnati, OH, ³UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ⁴Université de Paris, IMAGINE Institute, RAISE reference centre, Pediatric Immuno-Hematology and Rheumatology Unit, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, ⁵Hospital Sant Joan de Déu, Division of Pediatric Rheumatology, University of Barcelona, Barcelona, Spain, ⁶Swedish Orphan Biovitrum AG (Sobi), Basel, Switzerland
Background/Purpose: MAS is a life-threatening complication of rheumatic diseases, occurring most frequently in sJIA. The mainstay of MAS treatment is high dose GCs; however, GCs…
Abstract Number: 0471 • ACR Convergence 2021
Therapeutic Efficacy of BT-104, an Oral LANCL2 Agonist, for the Treatment of Systemic Lupus Erythematosus
Andrew Leber, Raquel Hontecillas, Nuria Tubau-Juni, Sarah Fitch, Jyoti Chauhan and Josep Bassaganya-Riera, Landos Biopharma, Blacksburg, VA
Background/Purpose: Systemic lupus erythematosus is a complex disease in which the immune system is dysfunctional at multiple levels including impaired regulatory responses, altered self-antigen processing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].